Description
Indication & Scope
LuYiPing® is a prescription dipeptidyl peptidase-4 (DPP-4) inhibitor indicated, together with diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus. It may be used as monotherapy or in combination with metformin, sulfonylureas, or insulin when additional glycemic control is needed.
- Mechanism: Vildagliptin selectively inhibits DPP-4, increasing endogenous GLP-1 and GIP levels, thereby enhancing glucose-dependent insulin secretion and reducing glucagon release.
- Drug class: DPP-4 inhibitor.
- Clinical use: Treatment of adults with type 2 diabetes mellitus as monotherapy or in combination with other antidiabetic agents.
| Generic Name | Vildagliptin Tablets |
| Brand Name | LuYiPing® |
| Ingredient | Vildagliptin |
| Dosage Form | Tablet |
| Package | 50 mg/tablet, 28 tablets/carton |
| Conditions Treated | Glycemic control in adults with type 2 diabetes mellitus |
| Taboos | Hypersensitivity to vildagliptin or any component of the product; type 1 diabetes mellitus; diabetic ketoacidosis; severe hepatic impairment |
| Place of origin | China |
| Prescription type | Prescription Drug (Rx) |
| Storage Conditions | Store below 30°C in a dry place, protected from light. |
| Manufacturer | Qilu Pharmaceutical Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval Number | H20193067 |
| Approval Date | October 24, 2023 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: The recommended dose is 50 mg once or twice daily depending on the treatment regimen. The maximum recommended daily dose is 100 mg.
Time: May be taken with or without food at the same time each day.
Instructions for use: Swallow the tablet whole with water. It may be used alone or in combination with metformin, insulin, or sulfonylureas. When used with a sulfonylurea, a lower sulfonylurea dose may be considered to reduce the risk of hypoglycemia.
Interaction: The risk of hypoglycemia may increase when used with insulin or sulfonylureas. Corticosteroids, thyroid hormones, thiazide diuretics, and sympathomimetics may reduce glycemic control. Liver function should be monitored during treatment.
Side effects: The most common adverse reactions include headache, dizziness, upper respiratory tract infection, nasopharyngitis, nausea, peripheral edema, arthralgia, and mild hypoglycemia when combined with insulin or sulfonylureas. Rare but serious adverse reactions include pancreatitis, elevated liver enzymes, angioedema, and bullous skin disorders.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is LuYiPing® used for?
It is used to improve blood glucose control in adults with type 2 diabetes mellitus together with diet and exercise.
Can LuYiPing® be used alone?
Yes. It can be used alone or in combination with metformin, insulin, or sulfonylureas.
Should LuYiPing® be taken with food?
No. It may be taken with or without meals.
Does LuYiPing® cause hypoglycemia?
When used alone, the risk is low. The risk increases when combined with insulin or sulfonylureas.
LuYiPing® | Vildagliptin | Type 2 Diabetes | DengYueRX
INN: Vildagliptin
Indications: Type 2 diabetes mellitus
Dosage Form: Tablet
Strength: 50 mg/Tablet
Original price was: $2.72.$2.31Current price is: $2.31.
